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Abstract
Several observations suggest a potential role of T-cell–
mediated immunity in the control of neuroblastoma
(NB). However, the generation of NB-specific cytotoxic
T lymphocytes (CTL) on T-cell priming with tumor
mRNA–transfected dendritic cells (DC) has never been
investigated before. In the present study, the feasibility
of this strategy has been analyzed, both in healthy
donors and in NB patients. Monocyte-derived DC were
raised from three human leukocyte antigen (HLA) A2+
NB patients and seven HLA-A1+ or HLA-A2+ healthy
donors transfected with mRNA from four NB cell lines
and cocultured with autologous CD8+ lymphocytes.
Expanded CTL expressed an effector/memory pheno-
type and a T cytotoxic 1–like profile of cytokine secre-
tion. CTL specificity was demonstrated by interferon-;
release on incubation with HLA-matched NB cell lines.
The latter cell lines, but not autologous T-cell blasts,
were lysed by CTL in an HLA-restricted manner. Cyto-
toxicity was found to involve the release of granzyme
B. When tested for reactivity against NB-associated
antigens, CTL from normal individuals recognized
anaplastic lymphoma–associated kinase (ALK) and
preferentially expressed antigen ofmelanoma (PRAME)
peptides only, whereas patients’ CTL reacted also to
survivin, telomerase, and tyrosine hydroxylase pep-
tides. This study demonstrates that DC transfected
with NB mRNA induce the generation of patients’ CTL
specific for different NB-associated antigens, sup-
porting the feasibility of NB T-cell immunotherapy.
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Introduction
Neuroblastoma (NB) is the most common extracranial solid
tumor in children. More than 50% of cases present with
metastatic disease on diagnosis. The majority of metastatic
tumors regress spontaneously in infants, whereas in older
children, disease progression takes place in spite of high-
dose chemotherapy and hematopoietic rescue with autologous
stem cell transplantation. The prognosis in this latter group of
patients is grim, with approximately 20% to 30% of them
surviving up to 5 years [1].
In the search for alternative therapeutic strategies for the
treatment of high-risk NB, immunotherapy has attracted much
interest [2]. In addition to approaches based on the stimulation
of the nonspecific arm of the immune system [3], protocols
have recently been designed to activate tumor-specific T-cell–
mediated mechanisms [4,5].
The expression of cancer testis antigens, such as NY-ESO-1
and members of the MAGE, BAGE, and GAGE families, has
been found both in NB cell lines and in primary tumors [6,7].
Furthermore, preferentially expressed antigen of melanoma
(PRAME) [8], survivin [9], a member of the inhibitors of apop-
tosis proteins, GD2 synthase [10], and telomerase [11] have
been detected in metastatic NB. Functional studies have
demonstrated thatmajor histocompatibility complex (MHC) class
I–restricted peptides from the MYCN oncoprotein [12], the
MAGE-1 antigen [13], anaplastic lymphoma–associated ki-
nase (ALK) [14], survivin [15], and the NY-ESO-1 antigen [16]
can be presented by human NB cell lines to human leukocyte
antigen (HLA)–matched CD8+ T cells, leading to the lysis of
antigen-presenting tumor cells. These data, together with the
demonstration that NB patients vaccinated with interleukin
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(IL) 2–secreting tumor cells mounted specific in vivo
antitumor responses [4], support the feasibility of NB
T-cell immunotherapy.
Myeloid dendritic cells (DC) are themost potent professional
antigen presenting cells (APC) and can be easily generated
in vitro from monocytes stimulated with granulocyte–
macrophage colony-stimulating factor (GM-CSF) and IL-4
[17]. DC pulsed with tumor cell lysates [18,19] or apoptotic
tumor cells [20], or transfected with tumormRNA [21–23] have
shown efficacy (both in vitro and in vivo) at inducing T-cell
responses against multiple tumor-associated antigens (TAA).
Tumor mRNA transfection is particularly attractive when
immunogenic epitopes of TAA are unknown [15,22].
Most DC-based clinical trials have been conducted in adult
cancer patients [23–28], but preliminary studies of vaccination
with tumor lysates or tumor mRNA pulsed DC have also been
performed in children with solid tumors [18,19,29]. Moreover,
a preclinical study has recently demonstrated that DC gen-
erated from normal donors and loaded or transfected with
NB-derived mRNA can stimulate T-cell–mediated responses
against tumor antigens presented by autologous DC [20].
No study has yet addressed the following issues, which
are critical to the clinical application of DC-based cancer vac-
cines in NB: 1) the ability of tumor RNA–transfectedDC inNB
patients to present TAA to autologous cytotoxic T lympho-
cytes (CTL); 2) the ability of CTL generated following this
approach to recognize and lyse malignant neuroblasts; and
3) the identification of NB TAA that are targets for these CTL.
In the present study, we demonstrate that mature mono-
cyte-derived DC from both normal donors and NB patients
can generate NB-specific CTL ex vivo following transfec-
tion with mRNA extracted from NB cell lines. These CTL




NB staging was performed according to the Interna-
tional Neuroblastoma Staging System [30]. After parental
informed consent had been obtained, heparinized periph-
eral blood samples were obtained from three stage 4 NB
patients at the end of induction chemotherapy following
G-CSF mobilization.
Cell Lines
The following tumor cell lines were used in the experi-
ments: NB cell lines GI-ME-N (HLA-A2+), IMR-32 (HLA-A2+),
SKNBE (HLA-A1+), SHSY5Y (HLA-A1+), and GI-LI-N (HLA-
A2+); T2 cell line; a TAP-deficient HLA-A2+ lymphoma cell line
(American Type Culture Collection, Rockville, MD). Tumor
cell lines were maintained in RPMI 1640 (Euroclone,
Wetherby, UK ) supplemented with 10% fetal bovine serum
(GIBCO Invitrogen, Carlsbad, CA), HEPES buffer, non-
essential amino acids, and antibiotics (Cambrex Bio Science
Verviers, Verviers, Belgium). Before being used as targets in
ELISPOTand cytotoxicity assays, NB cell lines were cultured
for 48 hours in the presence of 1000 U/ml human interferon
(IFN)-g (Imuchin; Boehringer Ingelheim Italia, Florence,
Italy), as described [31]. HLA typing of NB cell lines was
performed by a molecular technique [32].
DC Generation
Peripheral bloodmononuclear cells (PBMC) were isolated
by Ficoll-Hypaque density gradient centrifugation of patients’
heparinized peripheral blood samples or of buffy coat prep-
arations of seven healthy donors obtained from the blood
bank of our institute had been obtained. HLA typing had been
performed by a molecular technique [32].
Monocyte-enriched cell populations were then isolated
by Percoll (Pharmacia, Uppsala, Sweden) density gradient
centrifugation, resuspended in X-VIVO 15medium (Cambrex
Bio Science Verviers), and plated onto 12-well plates (Corn-
ing Incorporated, Corning, NY) at 3  105 per well. After
2 hours of incubation, nonadherent cells were removed,
and adherent cells were cultured in X-VIVO 15 medium
with 400 U/ml rGM-CSF (PeproTech EC, London, UK) and
50 ng/ml rIL-4 (ImmunoTools, Friesoythe, Germany) for
5 days. Immature DC underwent maturation by exposure to
125 U/ml rIL-6, 5 ng/ml recombinant tumor necrosis factor
(TNF)a , 5 ng/ml rIL-1b (Strathmann Biotech AG, Hamburg,
Germany), and 1 mg/ml prostaglandin E2 (Sigma-Aldrich, St.
Louis, MO) for 24 hours before transfection. In some experi-
ments, DC were subsequently divided into two aliquots, the
first of which was transfected with NB cell line mRNA (see
below) and cultured for 24 hours, whereas the second un-
manipulated aliquot was kept in culture for the same time.
The phenotype of mRNA-transfected and untransfected
DC cell populations was assessed by staining with CD14–
phycoerythrin (PE) (BD Biosciences, San Jose, CA), CD80–
fluorescein isothiocyanate (FITC) (DiacloneResearch, Besanc
on, France), CD40–PE (Diaclone Research), CD83–FITC
(Immunotech, Marseille, France) monoclonal antibody
(mAb), and flow cytometric analysis (FACSCalibur; BD Bio-
sciences) (CellQuest software, BD Biosciences, San Jose,
CA). Isotype-matched immunoglobulins (Caltag, Burlingame,
CA) were used as negative control. DC viability was as-
sessed by human Annexin V–FITC (Bender MedSystems
GmbH, Vienna, Austria) binding and FACS analysis. Results
were expressed as percentages of positive cells.
NB Cell mRNA Extraction and DC Transfection
mRNA was extracted from four NB cell lines (GI-ME-N,
SKNBE, SHSY5Y, and IMR-32) using the mRNA Isolation Kit
(Roche Diagnostics Gmbh, Mannheim, Germany) according
to the manufacturer’s protocol, pooled in equal ratio at a final
concentration of 200 mg/ml, and stored at 80jC until use.
DC transfection was performed using a nonlipid cationic
reagent (Transmessenger Transfection Reagent; Qiagen,
Chatworth, CA), as described by Liao et al. [33], with mod-
ifications. Briefly, 94 ml of transfection buffer was mixed with
8 ml of enhancer reagent and 5 ml of mRNA (1 mg). After
incubation for 5 minutes at room temperature, 12 ml of trans-
fection reagent was added, and incubation continued for
10 minutes at room temperature. Mature DC were collected,
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washed twice in phosphate-buffered saline (PBS; Sigma),
and resuspended in X-VIVO medium; 1  106 DC in 500 ml
were added to the transfection mixture. After incubation for
45 minutes at 37jC, DC were washed twice in PBS, re-
suspended in maturation cocktail, and cultured for addi-
tional 24 hours before use. To verify mRNA transfection
into DC, reverse transcription–polymerase chain reaction
(RT-PCR) analysis for tyrosine hydroxylase (TH) mRNA
was carried out on DC before and 1 or 24 hours after
transfection. In these experiments, DC were washed five
times with PBS before being subjected to RNA extraction.
Total RNA was extracted using Rneasy Mini Kit (Qiagen) and
subjected to RT-PCR as reported [34]. The primer sequence
was 5V-CATCACCTGGTCACCAAGTTC and 3V-GTG-
GTGTAGACCTCCTTCCA. The amplification profile was
as follows: 95jC for 10minutes (Taq activation), denaturation
at 95jC for 30 seconds, annealing at 60jC for 1 minute, and
extension at 72jC for 1 minute. Each cycle of amplification
was repeated 50 times. Ten microliters of each sample was
electrophoresed through a 1% agarose gel containing ethi-
dium bromide. The specificity of amplification products was
checked by confirming the known basepair sequence length.
Real-time RT-PCR was performed as described in Trager
et al. [35] and Cheung et al. [36].
CTL Generation
CD8+ T-cell populations (> 90% CD8+ cells) were pu-
rified from the PBMC of NB patients and normal donors by
immunomagnetic enrichment with CD8 MicroBeads (Miltenyi
Biotec GmbH, Bergisch Gladbach, Germany). CD8+ T cells
were cultured in 96-well plates (Corning Incorporated) at a
10:1 cell ratio with autologous transfected DC in RPMI 1640
supplemented with 10% heat-inactivated human AB serum
and 5 ng/ml rIL-7 (PeproTech EC). Lymphocytes underwent
four rounds of weekly stimulation with autologous transfected
DC and, starting from the third round of stimulation, 20 U/ml
rIL-2 (Proleukin; Chiron Italia Srl, Milan, Italy) was added to
the culture medium. Immunophenotypic and functional char-
acterizations of CTL were performed 7 days after the fourth
round of stimulation. CTL phenotype was studied by single or
double staining with CD3–FITC (BD Pharmingen, San
Diego, CA), CD8–PE (BD Biosciences), CD4–PE (BD Bio-
sciences), anti–TCR-a/b–PE (BD Pharmingen), CD16–
FITC (BD Pharmingen), CD45R0–TriColor (Caltag), and
anti–CCR7–PE (BD Pharmingen) mAbs, followed by FACS
analysis. Intracellular cytokine expression was analyzed by
intracellular staining with anti–IFN-g–FITC (Caltag), anti–
IL-4–PE (Caltag), and anti–TNF-a–PE (Caltag) mAbs, as
described [37]. Isotype-matched immunoglobulins (Caltag)
were used as negative control. Results were expressed as
percentages of positive cells.
Peptides
The following published HLA-A2–binding peptides were
synthesized: ILAKFLHWL from telomerase (hTERT) [38],
ELTLGEFLKL from survivin [39], SLLQHLIGL from PRAME
[40], and VLLWEIFSL from ALK [14]. The HLA-A2 peptide
from TH (ALLSGVRQV) was selected using HLA epitope–
binding prediction programs (BIMAS and SYFPEITHI). A
green fluorescence protein (GFP) peptide (KLLDSMHEV)
was used as an irrelevant peptide and was selected using
the same epitope prediction programs.
The peptides were manually synthesized using the stan-
dard method of solid-phase peptide synthesis, which follows
the 9-fluorenylmethoxycarbonyl (Fmoc) strategy, with minor
modifications [41]. The analysis of crude powders was per-
formed by high-performance liquid chromatography (HPLC)–
electrospray ionization–mass spectrometry (MS) using an
Agilent 1100 series LC/MSD ion-trap instrument. All synthe-
sized compounds were purified by reverse-phase HPLC on a
Shimadzu (Kyoto, Japan) LC-9A preparative HPLC equipped
with a Phenomenex C18 Luna column (21.20 250mm). The
molecular weights of the products were finally confirmed by
electrospray ion-trap MS. To test the HLA-A2–binding ability
of the selected peptides, in vitro cellular binding assays were
performed using the T2 cell line, as described [42].
ELISPOT Assays
ELISPOTassays for IFN-g and granzyme B were carried
out using MAIPS4510 Multiscreen-IP Millipore plates (Milli-
pore, Bedford, MA) coated overnight at 4jC with anti–IFN-g
mAb (clone 1-DK-1, 1 mg/ml; Mabtech, Nacka, Sweden) or
anti–granzyme mAb (clone GB10, 15 mg/ml; Mabtech), re-
spectively. Plates were then washed and blocked with PBS–
2% human albumin (Kedrion SpA, Lucca, Italia). CTL (3 
104) were cultured with 6  104 target cells (1:2 cell ratio) in
RPMI 1640–5% human AB serum in a final volume of 200 ml.
As targets, the T2 cell line (pulsed for 2 hours with 100 mM
synthetic peptide) or NB cell lines were used. Both targets
were g-irradiated (45 Gy) before being plated. The blocking
effect of anti–HLA class I mAb (TP25.99 was kindly provided
by Prof. Soldano Ferrone, Roswell Park Cancer Institute,
Buffalo, NY) was assessed by adding 10 mg/ml mAb to target
cells 30 minutes before culture with lymphocytes.
In some experiments, freshly isolated CD8+ T cells (5 
104) were tested against the peptide-pulsed T2 cell line (7 
104) that was g-irradiated before being plated.
After 20 hours of incubation at 37jC and 5% CO2,
ELISPOTassays were developed according to the manufac-
turer’s protocol. Spots were counted using an automated
ELISPOTreader (Bioreader 2000; Biosys, Karben, Germany).
Cytotoxicity Assays
The cytolytic activity of CTL was assessed against HLA-
matched NB cell lines or autologous phytohemagglutinin
blasts as targets by a standard 4-hour 51Cr release assay.
The effector/target (E:T) cell ratio ranged from 50:1 to 1:1. A
10-fold excess of unlabeled K562 cells was added to reduce
NK-like activity. Blocking experiments were performed by
adding anti–HLA class I TP25.99 mAb (10 mg/ml) to target
cells 30 minutes before culture with lymphocytes.
In some experiments, effector cells were pretreated with
concanamycin A (CMA; Sigma), an inhibitor of vacuolar-type
H+-ATPase, at 100 ng/ml for 2 hours. After CMA treatment,
effector cells were incubated with 51Cr-labeled target cells in
the cytotoxicity assay in the presence of CMA [43].
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Specific lysis was determined according to the formula: %
specific lysis = cpm (sample  spontaneous) / cpm (total 
spontaneous)  100.
Statistical Analysis
Statistical analysis of paired data was performed using
Wilcoxon rank test. Results were considered significant
when P < .05.
Results
Transfection of Mature DC with Pooled mRNA
from NB Cell Lines
Immature DC were generated in vitro from circulating
monocytes of three HLA-A2+ NB patients and seven HLA-
A1+ or HLA-A2+ normal donors. Tumor mRNA transfection
of mature DC leads to prolonged antigen presentation and
generation of CTL with high target avidity and cytotoxic po-
tential [33]. Therefore, in this study, DC were induced to ma-
ture (as described in Materials and Methods section) before
undergoing transfection with pooled mRNA extracted from
four NB cell lines (GI-ME-N, SKNBE, SHSY5Y, and IMR-32).
In three different experiments, qualitative RT-PCR analy-
sis showed that TH mRNA was absent from mature DC
before transfection but was present in DC both 1 and
24 hours after transfection. TH is an enzyme involved in
catecholamine biosynthesis that is expressed in NB cells
with high specificity [44]. The left panel of Figure 1A shows
one representative experiment. Real-time RT-PCR experi-
ments indicated that approximately 20 nmol TH/pg RNA
was expressed by 1-hour–transfected—but not by untrans-
fected—DC. One of three representative experiments per-
formed is shown on the right panel of Figure 1A. These results
demonstrate that the genetic information encoded by tumor-
derived mRNA was indeed transferred to DC.
The immunophenotype of mRNA-transfected and un-
transfected DC preparations was next investigated by
flow cytometry. Figure 1B shows the results of the experi-
ments performed with DC from all patients tested. Similar
results were obtained with control DC from normal donors
(not shown).
Untransfected and transfected DC were CD14 and
contained similar proportions of CD40+, CD80+, and CD83+
cells. The histograms of a representative experiment per-
formed with cells from patient 2 are shown in Figure 1C.
These results demonstrated that the transfection procedure
did not alter the immunophenotype of DC populations. Like-
wise, cell viability was consistently higher than 90% in both
untransfected and transfected DC (not shown).
Generation of NB-Reactive CTL from the Blood of NB
Patients and Healthy Donors
CD8+ T-cell populations were purified from the PBMC of
both patients and normal donors. For CTL priming, CD8+
lymphocytes underwent four weekly cycles of stimulation
with autologous DC transfected with NB mRNA and were
then expanded in rIL-2 before being characterized. Figure 2A
shows the results of immunophenotypic analyses per-
formed with CTL from all patients tested. Data with control
CTL from normal donors were similar (not shown).
Cells that were mostly CD3+, CD8+, TCR a/b+, CD4, and
CD16 displayed an effector/memory phenotype (CD45R0+
and CCR7+/) and a T cytotoxic 1 (Tc1)– like pattern of
cytokine secretion (IFN-g+, TNF+, and IL-4+/). Figure 2B
shows the histograms of a representative experiment per-
formed with cells from patient 2.
The ability of in vitro–expandedCTL to recognize NB cells
was investigated by IFN-g ELISPOT and 51Cr release cyto-
toxic assays using IFN-g–pretreated NB cell lines as targets.
Figure 3 shows that CD8+ T-cell lines both from NB patients
(patients 1 and 2, HLA-A2+) and normal subjects (donors 3,
5, and 6, HLA-A2+; donors 2 and 7, HLA-A1+) contained spe-
cific T cells secreting IFN-g in response to HLA-matched NB
cells. The frequency of specific spots in the CTL populations
shown in Figure 3 ranged from 37 to 62 per 3  104 primed
Tcells in NB patients and from 13 to 159.5 per 3 104 primed
T cells in normal donors. IFN-g secretion by CTL was down-
regulated by anti–HLA class I antibody, irrespective of pa-
tient or donor origin (Figure 3). A significant difference was
detected by pooling the results and comparing paired IFN-g
spots in the absence and in the presence of anti–HLA class I
mAb (P < .0078, Wilcoxon rank test).
When tested for cytolytic activity, CTL from both NB
patients (patients 1 and 2, HLA-A2+) and healthy donors
(donors 1, 3, 4, and 5, HLA-A2+; donor 7, HLA-A1+) lysed
HLA-matched NB cells, but not autologous T-cell blasts
(Figure 4). NB target cell lysis was reduced in all samples
by the addition of anti–HLA class I antibody. (Figure 4). A
significant difference was detected by pooling the results
and by comparing paired percent-specific lysis values (50:1
E:T ratio) in the absence and in the presence of anti–HLA
class I mAb (P < .0005, Wilcoxon rank test).
In further experiments, CTL from normal donors were
tested in ELISPOTand cyotoxicity assays against untreated
HLA-matched NB cell lines with minimal expression of HLA
class I, which would more closely mimic in vivo interactions
between CTL and tumor cells. As expected, the frequency
of specific IFN-g spots was lower than that detected against
the same IFN-g pretreated NB cell lines (see above) and
ranged from 11 to 47 per 3  104 primed T cells. CTL were
also able to lyse untreated NB cell lines, even if the spe-
cific lysis was only 36% of that detected against the same
IFN-g–pretreated NB cell lines.
Taken together, these results indicate that NB-reactive
CTL can be generated in vitro from NB patients and normal
subjects on incubation with autologous DC transfected with
tumor mRNA. Tumor cell recognition by CTL implies that
endogenous TAA peptides are presented as HLA/peptide
complexes on the NB cell surface.
To investigate themechanism(s) of target cell lysis involved
inCTL-mediatedNBcell killing,ELISPOTassays for granzyme
B secretion were performed. CTL populations from two NB
patients (patients 1 and 2, HLA-A2+) and from two healthy
donors (donors 4 and 5, HLA-A2+) efficiently secreted
granzyme B in response to HLA-matched NB cell lines
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(Figure 5), suggesting that NB-reactive CTL lysed their spe-
cific targets through a granule exocytosis–dependent mech-
anism [45]. This conclusion was reinforced by the finding
that the addition of the specific H+-ATPase inhibitor CMA [43]
in cytotoxic assays abrogated NB cell lysis (not shown).
NB-Reactive CTL Generated by Incubation
with Tumor RNA–Transfected DC Recognize
Different NB-Associated Antigens
The fine antigen specificity of NB-reactive CTL generated
on incubation with autologous DC transfected with tumor
mRNA was investigated using a panel of HLA-A2 peptides
from known TAA. CTL from HLA-A2+ subjects were tested in
ELISPOTassays for IFN-g secretion using peptide-pulsed T2
cells as targets. Figure 6 shows the results obtained with NB-
reactive CTL from HLA-A2+ patients (patients 1, 2, and 3)
(Figure 6, left panel ) and normal donors (donors 4, 5, and 6)
(Figure 6, right panel ).
CTL from the latter individuals recognized both PRAME
and ALK peptides, but not survivin or hTERT peptides. CTL
from patients 1 and 2 recognized peptides from survivin,
PRAME, ALK, hTERT, and, in addition, TH, whereas CTL
Figure 1. Characterization of mature DC transfected with mRNA from NB cell lines. (A) Mature DC derived from NB patients and normal donors were transfected
with pooled mRNA extracted from four NB cell lines and analyzed for the presence of tumor-derived TH transcripts by qualitative and real-time RT-PCR. Left panel:
RT-PCR analysis of TH gene expression was performed on total RNA extracted from DC before and after transfection (1 and 24 hours); pooled mRNA from NB cell
lines was used as positive control. CTR-negative control; MW, molecular weight markers. Right panel: Real-time RT-PCR analysis of TH gene expression was
performed on total RNA extracted from DC before and 1 hour after transfection. Results are expressed as nanomoles of TH per picogram of RNA. (B) Mature DC
were divided into two aliquots, the first of which was transfected with NB cell line mRNA and cultured for 24 hours, whereas the second unmanipulated aliquot was
kept in culture for the same time. The immunophenotype of these cell fractions was next investigated by flow cytometry. The ranges of the results obtained with all
patients tested are shown. Results are expressed as percentages of positive cells. The histograms of a representative experiment performed with cells from patient
2 are shown in (C). Empty profiles indicate staining with isotype-matched control immunoglobulins; black profiles refer to staining with specific mAb.
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from patient 3 recognized survivin, PRAME and ALK, but
not hTERTand TH peptides.
PRAME,ALK, survivin, andTH-specific cellsweredetected
by ELISPOT in CD8+ cells that were freshly isolated from
patients 1 and 2 (mean frequencies of 3/100’000, 4/100’000,
2/100’000, and 1,5/100’000, respectively). CD8+ cells freshly
isolated from two normal donors did not react to these pep-
tides. In contrast, telomerase-specific cells were detected in
CD8+ cells from two normal donors (4/100’000) and in CD8+
cells from patient 1 (1/100’000), but not from patient 2.
Discussion
In this study, we have investigated the ability of DC trans-
fected with tumor-derived mRNA to generate CTL that are
able to recognize and kill specifically human NB cells. For the
first time, the feasibility of this strategy has been demon-
strated here both for patients with metastatic NB and for
healthy donors.
The grim prognosis of children presenting with dissemi-
nated NB at diagnosis has fostered the quest for novel
therapeutic strategies, among which immunotherapy holds
promise. Both murine and chimeric anti-GD2 antibodies
have been tested in numerous clinical trials, with inter-
esting results [2]. In addition, IL-2 administered as a re-
combinant cytokine or tumor vaccine has shown some
therapeutic activity [4,5,46].
In view of their potent APC functions, DChave beenwidely
tested both in preclinical and in clinical studies to boost
antitumor immunity [47]. The nature of antigens and the
timing of DC pulsing are critical factors to the generation of
DC with potent immunostimulatory activities [47]. Among
other strategies, the transfection of DC with tumor-derived
mRNA has been shown to stimulate the production of anti-
tumorCTL directed toward different TAA [23], thusminimizing
the risk of tumor escape due to single epitope mutation [48].
This is likely to be of functional importance because anti-NB
CTL, raised in vitro against individual NB TAA, may be
ineffectual in vivo as tumor antigen escape mutants may be
readily selected if only a single TAA epitope is targeted.
Here, tumor mRNA–transfected DC were found to induce
the in vitro expansion of CTL reactive to an array of TAA
and that had an effector/memory immunophenotype and
a Tc1-like cytokine profile. Thus, these CTL released IFN-g
on incubation with HLA-matched NB cell lines and, most
importantly, killed the same cell lines in an HLA-restricted
Figure 2. Immunophenotype of in vitro–expanded CD8+ T lymphocytes upon priming with autologous DC transfected with NB mRNA. The immunophenotypic
profile of in vitro–expanded CTL was assessed by flow cytometry using fluorochrome-conjugate mAbs. Intracellular cytokine staining was performed as detailed in
Gattorno et al. [37]. (A) The ranges of the results from all patients tested are shown. Results are expressed as percentages of positive cells. (B) The histograms of a
representative experiment performed with cells from patient 2 are shown. Empty profiles indicate staining with isotype-matched control immunoglobulins; black
profiles refer to staining with specific mAbs. Numbers on the top right refer to percentages of positive cells.
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Figure 3. NB specificity of CTL generated on priming with autologous DC transfected with NB mRNA. CD8+ T-cell lines derived from two NB patients (patients 1
and 2, both HLA-A2+) and five healthy donors (donors 3, 5, and 6, HLA-A2+; donors 2 and 7, HLA-A1+) were assessed for IFN-c release by ELISPOT assays. T
cells were cultured with medium alone (medium) or with HLA-matched NB cell lines at a 1:2 cell ratio, in the absence () or in the presence (+) of anti –HLA class I
mAb. Indicated spot numbers per seeded lymphocyte represent the mean values of three replicates. One of three representative experiments performed for each
subject is shown.
Figure 4. NB cell lysis by CTL expanded in vitro using autologous DC transfected with NB mRNA. CTL expanded from two NB patients (patients 1 and 2, both
HLA-A2+) and five healthy donors (donors 1, 3, 4, and 5, HLA-A2+; donor 7, HLA-A1+) were tested for cytotoxic activity in 4-hour 51Cr release assays against
HLA-matched NB cell lines or autologous T-cell blasts in the absence () or in the presence (+) of anti –HLA class I mAb. Results are expressed as percent-
specific lysis at a 50:1 effector/target ratio. Numbers represent the mean values of three replicates. One of three representative experiments performed for each
subject is shown.
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manner. CTL from healthy donors reacted consistently with
PRAME and ALK peptides, whereas the CTL of patients
displayed broader reactivity, including survivin, telomerase,
and TH peptides, in addition to PRAME and ALK peptides.
These differences appeared to be related to the naı¨ve CTL
responses triggered by mRNA-transfected DC in healthy
donors, as opposed to the stimulation of memory CTL pre-
cursors in patients. Thus, freshly isolated CD8+ cells from
patients, but not from normal donors, were found to contain
peptide-specific cells in a range (1/100’000 to 8/100’000)
similar to that reported by others [49,50]. The only exception
was represented by the telomerase peptide that was recog-
nized by both normal and patient CD8+ cells. This result has
been reported previously [51].
Three findings from our study point to the predominant
involvement of the granule exocytosis pathway in the CTL-
mediated killing of NB cells: 1) CTL released granzymeB only
on incubation with IFN-g–pretreated cell lines; 2) CMA
abrogated NB cell lysis [43]; and 3) CTL-mediated lysis of
tumor cells was dampened by anti–HLA class I antibody,
pointing to a minor involvement, if any, of HLA-unrestricted
mechanisms such as the Fas or the TNF-related apoptosis-
inducing ligand receptor pathways [45]. These findings are
consistent with the silencing of the caspase 8 gene reported
in most NB cell lines and primary tumor cells from stage 4 pa-
tients [52] because apoptosis triggered by members of the
TNF family of death receptors involves caspase 8 activation.
Previously, it has been demonstrated that CD40 ligand–
stimulated human B cells, following transfection with NB cell
line mRNA, promoted the generation of tumor-specific CTL
from the peripheral blood of normal individuals and NB
patients [15]. Thus, this immunotherapeutic approach ap-
pears to be feasible for both myeloid DC and B cells.
The clinical feasibility of our approach is supported by data
from a recently published phase I study performed in NB
patients who were vaccinated with autologous DC pulsed
Figure 5. Granzyme B release by NB-specific CTL on incubation with HLA-matched NB cell lines. CTL expanded from two NB patients (patients 1 and 2, both HLA-
A2+) and two healthy donors (donors 4 and 5, HLA-A2+) were tested for granzyme B release by ELISPOT assays. T cells were cultured with medium alone
(medium) or with HLA-matched NB cell lines at a 1:2 cell ratio. Indicated spot numbers per seeded lymphocyte represent the mean values of three replicates. One
of three representative experiments performed for each subject is shown.
Figure 6. NB-specific CTL recognize multiple TAA. CTL from three HLA-A2+ NB patients (patients 1, 2, and 3) and three HLA-A2+ healthy donors (donors 4, 5, and
6) were assayed by IFN-c ELISPOT using as target a T2 cell line pulsed with HLA-A2 synthetic peptides of survivin, PRAME, ALK, hTERT, and TH, respectively.
Indicated spot numbers per seeded lymphocyte represent the mean values of three replicates after the subtraction of spots obtained with T2 cells pulsed with an
irrelevant control peptide (GFP). One of three representative experiments performed for each subject is shown.
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with primary tumor lysates that showed minimal toxicity [29].
Furthermore, a preclinical study demonstrated that NB
mRNA–transfected DC from normal donors can be manu-
factured at clinical grade [20]. This latter study, however,
neither addressed the feasibility of the approach in patients
nor demonstrated that tumor-specific CTL raised by incuba-
tion with tumor mRNA–transfected DC lysed the cell lines
from which mRNA had been extracted.
How well will NB cells be killed by the MHC-restricted CTL
induced by pulsed DC? NB cells have low to absent expres-
sion of surface HLA class I molecules and costimulatory
molecules, as well as multiple abnormalities of the related
antigen processing machinery, implying that they may simply
not be a target even for a specific CTL response [31,53].
However, these defects can be corrected, at least in part, by
NB cell incubation with IFN-g or retinoids [31,54], and this
study showed that some recognition of NB cells expressing
low levels of HLA class I by CTL can occur in vitro even in the
absence of IFN-g pretreatment. In addition, tumor-specific
CTL responses have been documented in NB patients who
were vaccinated with NB cells engineered to secrete IL-2, a
potent inducer of IFN-g production [4]. Nonetheless, NB
immunotherapy with tumor mRNA–transfected autologous
DC or tumor-specific CTL may be more efficacious if com-
bined with approaches aimed at increasing MHC and tumor
antigen expression by malignant cells.
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